uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK

Brain Res. 2008 Sep 22:1231:121-31. doi: 10.1016/j.brainres.2008.06.115. Epub 2008 Jul 8.

Abstract

We have previously observed that soluble urokinase plasminogen activator receptor (suPAR) prevents impairment of cerebrovasodilation induced by hypercapnia and hypotension after hypoxia/ischemia (H/I) in the newborn pig. In this study, we investigated the role of low-density lipoprotein-related protein (LRP) receptor and the ERK isoform of mitogen activated protein kinase (MAPK) in uPA-mediated impairment of vasodilation after H/I in piglets equipped with a closed cranial window. CSF uPA increased from 9+/-2 to 52+/-8 and 140+/-21 ng/ml at 1 and 4 h after H/I, respectively. The LRP antagonist receptor associated protein (RAP) and anti-LRP antibody blunted the increase in CSF uPA at 1 h (17+/-2 ng/ml) but not 4 h post insult. uPA detectable in sham-treated cortex by immunohistochemistry was markedly elevated 4 h after H/I. Phosphorylation (activation) of CSF ERK MAPK was detected at 1 and 4 h post H/I and blocked by RAP. Exogenous uPA administered at 4 h post H/I further stimulated ERK MAPK phosphorylation, which was blocked by RAP. Pre-treatment of piglets with RAP, anti-LRP, and suPAR completely prevented, and the ERK MAPK antagonist U 0126 partially prevented, impaired responses to hypotension and hypercapnia post H/I, but none of these antagonists affected the response to isoproterenol. These data indicate that uPA is upregulated after H/I through an LRP-dependent process and that the released uPA impairs hypercapnic and hypotensive dilation through an LRP- and ERK MAPK dependent pathway. These data suggest that modulation of uPA upregulation and/or uPA-mediated signal transduction may preserve cerebrohemodynamic control after hypoxia/ischemia.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / pharmacology
  • Cerebral Arteries / drug effects
  • Cerebral Arteries / metabolism*
  • Cerebral Arteries / physiopathology
  • Female
  • Hypercapnia / metabolism
  • Hypercapnia / physiopathology
  • Hypotension / metabolism
  • Hypotension / physiopathology
  • Hypoxia-Ischemia, Brain / drug therapy
  • Hypoxia-Ischemia, Brain / metabolism*
  • Hypoxia-Ischemia, Brain / physiopathology
  • Low Density Lipoprotein Receptor-Related Protein-1 / metabolism*
  • MAP Kinase Signaling System / drug effects
  • Male
  • Mitogen-Activated Protein Kinase 3 / metabolism*
  • Phosphorylation / drug effects
  • Sus scrofa
  • Time Factors
  • Up-Regulation / drug effects
  • Urokinase-Type Plasminogen Activator / metabolism*
  • Urokinase-Type Plasminogen Activator / pharmacology
  • Vasodilation* / drug effects

Substances

  • Antibodies
  • Low Density Lipoprotein Receptor-Related Protein-1
  • Mitogen-Activated Protein Kinase 3
  • Urokinase-Type Plasminogen Activator